NASDAQ:SIGA • US8269171067
The current stock price of SIGA is 5.47 USD. Today SIGA is down by -0.09%. In the past month the price decreased by -17.62%. In the past year, price decreased by -1.97%.
ChartMill assigns a technical rating of 0 / 10 to SIGA. When comparing the yearly performance of all stocks, SIGA is a bad performer in the overall market: 75.38% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to SIGA. SIGA gets an excellent profitability rating and is at the same time showing great financial health properties.
On March 10, 2026 SIGA reported an EPS of -0.08 and a revenue of 3.79M.
For the next year, analysts expect an EPS growth of 400.13% and a revenue growth 132.36% for SIGA
Over the last trailing twelve months SIGA reported a non-GAAP Earnings per Share(EPS) of 0.31. The EPS decreased by -62.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 43.37% | ||
| ROA | 32.26% | ||
| ROE | 36.72% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.96 | 943.209B | ||
| JNJ | JOHNSON & JOHNSON | 20.78 | 585.582B | ||
| MRK | MERCK & CO. INC. | 22.4 | 287.316B | ||
| PFE | PFIZER INC | 9 | 155.235B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.31 | 122.147B | ||
| ZTS | ZOETIS INC | 16.31 | 50.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.88 | 26.934B | ||
| VTRS | VIATRIS INC | 5.5 | 16.085B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.56 | 11.659B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.158B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.518B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.968B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.91 | 4.412B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
IPO: 1997-09-09
SIGA TECHNOLOGIES INC
31 East 62Nd Street
New York City NEW YORK 10065 US
CEO: Phillip L. Gomez
Employees: 46
Phone: 12126729100
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
The current stock price of SIGA is 5.47 USD. The price decreased by -0.09% in the last trading session.
SIGA TECHNOLOGIES INC (SIGA) has a dividend yield of 10.96%. The yearly dividend amount is currently 0.6.
SIGA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
SIGA TECHNOLOGIES INC (SIGA) operates in the Health Care sector and the Pharmaceuticals industry.
SIGA TECHNOLOGIES INC (SIGA) currently has 46 employees.
SIGA TECHNOLOGIES INC (SIGA) has a market capitalization of 391.71M USD. This makes SIGA a Small Cap stock.